pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-151b |
Genomic Coordinates | chr14: 100109419 - 100109514 |
Description | Homo sapiens miR-151b stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-151b | ||||||||||||
Sequence | 60| UCGAGGAGCUCACAGUCU |77 | ||||||||||||
Evidence | Experimental | ||||||||||||
Experiments | RAKE | ||||||||||||
SNPs in miRNA |
|
||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CBLB | ||||||||||||||||||||
Synonyms | Cbl-b, Nbla00127, RNF56 | ||||||||||||||||||||
Description | Cbl proto-oncogene B | ||||||||||||||||||||
Transcript | NM_170662 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CBLB | |||||||||||||||||||||
3'UTR of CBLB (miRNA target sites are highlighted) |
>CBLB|NM_170662|3'UTR 1 CAGCCAGAACTGTAGACACCAAAATGGAAAGCAATCGATGTATTCCAAGAGTGTGGAAATAAAGAGAACTGAGATGGAAT 81 TCAAGAGAGAAGTGTCTCCTCCTCGTGTAGCAGCTTGAGAAGAGGCTTGGGAGTGCAGCTTCTCAAAGGAGACCGATGCT 161 TGCTCAGGATGTCGACAGCTGTGGCTTCCTTGTTTTTGCTAGCCATATTTTTAAATCAGGGTTGAACTGACAAAAATAAT 241 TTAAAGACGTTTACTTCCCTTGAACTTTGAACCTGTGAAATGCTTTACCTTGTTTACAGTTTGGCAAAGTTGCAGTTTGT 321 TCTTGTTTTTAGTTTAGTTTTGTTTTGGTGTTTTGATACCTGTACTGTGTTCTTCACAGACCCTTTGTAGCGTGGTCAGG 401 TCTGCTGTAACATTTCCCACCAACTCTCTTGCTGTCCACATCAACAGCTAAATCATTTATTCATATGGATCTCTACCATC 481 CCCATGCCTTGCCCAGGTCCAGTTCCATTTCTCTCATTCACAAGATGCTTTGAAGGTTCTGATTTTCAACTGATCAAACT 561 AATGCAAAAAAAAAAAAGTATGTATTCTTCACTACTGAGTTTCTTCTTTGGAAACCATCACTATTGAGAGATGGGAAAAA 641 CCTGAATGTATAAAGCATTTATTTGTCAATAAACTGCCTTTTGTAAGGGGTTTTCACATAACATAGAGGAGCTTCCCTTT 721 TTTGTTTAAGTTTTGTAACCTTTAATCCTCCATATTCTCATGTCTGTCATCCCAGGGGTGTCACAACTGTAAAAATCTAC 801 AATATTAGAAAGCAGCTACTACAGATGTGGAAGAGAGAACACTTGTATAAGACAATGCTGTACTGAAGTTATATAACAAG 881 GTCCCCTGATACTTATGCCTGCATTACTTTGAGGGATGCTGAATGAGAGGACCATCTCCCTGAAATATATTAATAATTTT 961 CAGATAAAATTATGAACATAACATACCTTTTCTCAAGTGGAATTAGAGTTCATTTCCCATTTAAGTGATTACACTCTATC 1041 TCCTAAGAGCTGTGGGAACCAGTTCATATTGCAGTGGAAACATTAACTCTTCGTTGCACTGTTGAGTGTCAAGGCTACTG 1121 TGGCAATGTTTTTTGCAAAGTTCTCAGTAATTTTCTCTCTGCAATCAAATTAGAGTTCATATTTAATTTGCAGATTCTCT 1201 CATTCATTGCTCCACACTGCTTTATCAAATCAGGTGAAAGAAATTAATGTAGTTTTGCCTATTTTACAAAATGGTGGTTG 1281 GTTCTTTAAACACCATGTTATTACTCTTAATAAATCTACAAATATTTATTGAGCATCTATGATATGCTTGGTGCTGTTAG 1361 GCACTGTGTTTTTAAAGCACAAACTCTCAAAAGCTGATTCCAGCGTAATGTTTTATTTTTGTTTTTCTGTGTTTTTTATG 1441 ACAAAGTCTGTCTGATAGACAAAGCCTGGAAGGTTTCCCCCAGGGCTTTAGAATTTAGAATTAGCTGGTTTTCATTTCAA 1521 ATGGGAAATTAATGGAGAAATGAGATAAAATCATCTCTGTGTAAATGCTTGAACCCACAGAAAGTTTTCTAAATATGGAC 1601 TAATTGTGGGTTTGTGCATATTTCTGTGTCTCCTCTTTTCACTTCACACCCACCATGATATAAAAAGATGCATCAGAGAG 1681 TGAGCCTGCCTTCAGGACCTGAAAGGACATGACTGAACATCTAGTAGATCTGGTGGAAATTAATGTTATACAAAAGACAC 1761 GTAGACTAAGTTGACCCTGGGAGAGGAGTTAATACATTCCTTTGCAAAGTGACATGTGCCCTTTTTTTGACAGTCTGGCT 1841 TTCATGGTATGAGATGAGGACTCACAGGCCTTGGGTAATTTCTGCTTTTGTATGAATTTTTTCAGATGGTTCTGAGCTGG 1921 TTATGTCCCTGGAGGGGAATTTTTCATTTGCCTTAGATGTTCTTCCCATGAGTAGGTACATGAGTGAAGTTTCTTACACT 2001 TTTAAAATTGCATTGGCAAATTTTCTTTTGCTTTATGAACCCCTGTTTTGTCATTATGATTTTTCACTTGTTTTAACAGT 2081 TTCAGATGTCACCTTGGAATAGCACTGTTTATTTTGGCCTTTTTATGATTGCTGATGATAGGTACAGTCTAAAGGCCAAA 2161 AGTTGCCACTTCATTGTGATAACATTGTTGCAACATTCCTAATATATTAGAGAATGATGTAAAATAAGAATGTTAGAGAA 2241 CATAGCACATTCTCATTCAGTTTATAAACAATATTTGAAAATTTCCAGTGAGAATTAAAAAAGGACTAGTGATGATATAG 2321 CAAACCTGGACCTGAAATTTGGGGGTGGGGGGTGGGGGGATATCTGTTTTGCAGAGAAAATTTACCAGCCTCCAGCAAAA 2401 TCTCTGCATCTTGTACTCAATAGCAACCATTAGTATTGTCATTTAAAAAGAATGAATCAAAAATTCATACGTAATGGAAT 2481 GAAAAGAGGAAAACTTTCTATTAAACACTGTCAAGAAAGACCCATTGCTATCTATCACCTATGAAATTAAACCTAAAAAA 2561 ATTTTTTTTTATTGTAAAAGCGACTGCTCGTTGATGTCTGGAAGTGATCCAGACTTTGTTTCACTGTGATCCAAAAAGTT 2641 AGACATTCCTTCCATTTCTCAAGATTTGGTAACAATTTTTTTTTAAGTCAGCATTTCATATAATACATAAAATTAAGACA 2721 AATTAACTTACTGATATGTGGCCAATATCAACCCTTCTCACCCAACCCAAACATGTTCTGGAGATAGAAGGACTTATCCT 2801 CAATTATATTCCAGTAAATTTATCTCCATAATCTGTTTTATCCCCTAATGTATGATATATCTCACCAAATTTTTCTAGAA 2881 TTGAATAAAAGCAGTTTTTGCTTAACTTGAATTTCCTTCCACAAATACAACCTTCAGCTCTTCCCTCTCTGTTTCCCTTT 2961 TGCCCACATTGCAAATAGTCTTCATAATAGAACCCTCACTGCAACTTAAAAGGGTCCCATTTCTTAACTCAGCATTTCAT 3041 ATACCAAGAACACTTGCAAAGATTTCTTCATAATGTGATTTTTTAATTTTTCAGTTCCAGAAGCATTTCCTACAGTTCGA 3121 ACGTTATTTTTTCTCTCAGATTTTCAACTTGAAGCTTTGATTTGCACTGAATTAACTTGGATAAAATTTTAGTTTCTCTC 3201 TTCAGCTAACAGATTTGGAAGCAAATTACAGTATACTTGAATAATTCAGGTACTACCTGTTGACCTGGAATTTTAGTGAT 3281 TCTGGGAAAGTTTTCCAGACAAAGACACCAATAGAGTGAAGGGTTTTTTCCCCAATTACTATTTTATTGTTTTTTAAAAT 3361 GCCTTTTTAAAACTTGTGTGATGTGGCAAAATAGTCATATGTTCAATTAATTTATATTTTATTCATTCCTTTTCAATTCT 3441 GGTTATTATGTAACCTCAAGTACTTTATCTGTTCTTTTAAAGTATTTTATAAAATGAACGTTAACTAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HeLa | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in Chi_124B_2A8_130_50. RNA binding protein: AGO. Condition:HeLa cell miR-124 + B
... - Chi SW; Zang JB; Mele A; Darnell RB, 2009, Nature. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Chi SW; Zang JB; Mele A; Darnell RB - Nature, 2009
MicroRNAs (miRNAs) have critical roles in the regulation of gene expression; however, as miRNA activity requires base pairing with only 6-8 nucleotides of messenger RNA, predicting target mRNAs is a major challenge. Recently, high-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation (HITS-CLIP) has identified functional protein-RNA interaction sites. Here we use HITS-CLIP to covalently crosslink native argonaute (Ago, also called Eif2c) protein-RNA complexes in mouse brain. This produced two simultaneous data sets-Ago-miRNA and Ago-mRNA binding sites-that were combined with bioinformatic analysis to identify interaction sites between miRNA and target mRNA. We validated genome-wide interaction maps for miR-124, and generated additional maps for the 20 most abundant miRNAs present in P13 mouse brain. Ago HITS-CLIP provides a general platform for exploring the specificity and range of miRNA action in vivo, and identifies precise sequences for targeting clinically relevant miRNA-mRNA interactions.
LinkOut: [PMID: 19536157]
|
CLIP-seq Support 1 for dataset GSM4903825 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / PID14_NS |
Location of target site | NM_170662 | 3UTR | AAAGAGAACUGAGAUGGAAUUCAAGAGAGAAGUGUCUCCUCCUCGUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161237 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset Chi_124B_2A8_130_50 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | HeLa / HeLa cell miR-124 + B |
Location of target site | ENST00000264122.4 | 3UTR | GAGAGAAGUGUCUCC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 19536157 / Chi_HITSCLIP |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
25 hsa-miR-151b Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT249674 | SLC39A9 | solute carrier family 39 member 9 | 2 | 4 | ||||||||
MIRT366296 | GDI1 | GDP dissociation inhibitor 1 | 2 | 4 | ||||||||
MIRT451313 | LGALS3BP | galectin 3 binding protein | 2 | 2 | ||||||||
MIRT467467 | SMYD1 | SET and MYND domain containing 1 | 2 | 4 | ||||||||
MIRT477248 | ERGIC2 | ERGIC and golgi 2 | 2 | 2 | ||||||||
MIRT489948 | RFX2 | regulatory factor X2 | 2 | 2 | ||||||||
MIRT490364 | SLC6A1 | solute carrier family 6 member 1 | 2 | 4 | ||||||||
MIRT494531 | BCL7A | BCL tumor suppressor 7A | 2 | 2 | ||||||||
MIRT500190 | BARX1 | BARX homeobox 1 | 2 | 4 | ||||||||
MIRT511912 | FKBP1A | FK506 binding protein 1A | 2 | 2 | ||||||||
MIRT524875 | ARHGDIA | Rho GDP dissociation inhibitor alpha | 2 | 6 | ||||||||
MIRT555338 | PPP1R3B | protein phosphatase 1 regulatory subunit 3B | 2 | 4 | ||||||||
MIRT557122 | HOXA3 | homeobox A3 | 2 | 2 | ||||||||
MIRT559034 | C20orf24 | chromosome 20 open reading frame 24 | 2 | 4 | ||||||||
MIRT559824 | SLPI | secretory leukocyte peptidase inhibitor | 2 | 2 | ||||||||
MIRT568547 | AKT2 | AKT serine/threonine kinase 2 | 2 | 2 | ||||||||
MIRT568714 | TMEM30B | transmembrane protein 30B | 2 | 2 | ||||||||
MIRT569827 | CRMP1 | collapsin response mediator protein 1 | 2 | 2 | ||||||||
MIRT687618 | LYRM4 | LYR motif containing 4 | 2 | 2 | ||||||||
MIRT689949 | MANSC1 | MANSC domain containing 1 | 2 | 2 | ||||||||
MIRT690433 | FAM71F2 | family with sequence similarity 71 member F2 | 2 | 2 | ||||||||
MIRT694845 | KRT80 | keratin 80 | 2 | 2 | ||||||||
MIRT697594 | YME1L1 | YME1 like 1 ATPase | 2 | 2 | ||||||||
MIRT697848 | UBE2Z | ubiquitin conjugating enzyme E2 Z | 2 | 2 | ||||||||
MIRT719553 | CBLB | Cbl proto-oncogene B | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|